Who are Flupentixol melitracen tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flupentixol-melitracen-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Flupentixol melitracen tablets — Competitive Intelligence Brief

Flupentixol melitracen tablets (Flupentixol melitracen tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Typical antipsychotic + tricyclic antidepressant combination. Area: Psychiatry.

marketed Typical antipsychotic + tricyclic antidepressant combination Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Flupentixol melitracen tablets (Flupentixol melitracen tablets) — Peking University Third Hospital. Flupentixol is a typical antipsychotic that blocks dopamine D2 receptors, while melitracen is a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake, together providing antipsychotic and antidepressant effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flupentixol melitracen tablets TARGET	Flupentixol melitracen tablets	Peking University Third Hospital	marketed	Typical antipsychotic + tricyclic antidepressant combination	Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Typical antipsychotic + tricyclic antidepressant combination class)

Peking University Third Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flupentixol melitracen tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/flupentixol-melitracen-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab